



search  [Advanced Search](#)

Leading the way in experimental and clinical research in hematology

[Home](#) [About](#) [Authors](#) [Submit](#) [Subscriptions](#) [Classifieds](#) [Blood Journals](#)

[Current Issue](#) [First Edition](#) [Collections](#) [All Issues](#) [Abstracts](#) [Article Types](#) [Video Library](#)

## Prophylactic Treatment with New Recombinant Factor IX Innonafactor (Russia) in Adolescent and Adult Patients with Hemophilia B

Ekaterina Shiller, Victor Petrov, Pavel Svirin, Vladimir Vdovin, Igor Koltunov, Artyom Bullih, Michael A Maschan, Dmitry Kudlay, and Ekaterina Klykova

Blood 2017 130:4895;

[Article](#) [Info & Metrics](#)

### Abstract

#### Background:

Group of patients with severe and mild forms of hemophilia B was treated with Innonafactor in prophylactic regime during 26±1 weeks. Results based on the evaluation of the frequency of bleedings development during the study period.

#### Aim:

To assess the efficiency and safety of rIX Innonafactor (SJC "GENERIUM", Russia) in prophylactic treatment of adolescent and adult previous treated patients with severe and mild forms of hemophilia B (IX ≤2%).

#### Methods:

15 Caucasian men aged between 12 to 31 years (avg 20.5±8.4) with mild (5 – 33.3%) and severe (10–66.7%) forms of hemophilia B were including to study. All patients received prophylactic treatment in dose 45±5 IU two times per week during 26 weeks. In cases of bleedings Innonafactor was use on demand. There were registered frequency and heaviness of bleedings in time of treatment.

#### Results:

7 patients (46.7%) had 18 bleeding episodes in 72 hours after Innonafactor infusion (avg 1.2±1.7) during treatment. Most of them were traumatic, 5 spontaneous bleedings in mild and easy forms were registered only in 3 patients (20%).

Before the start of treatment 9 patients (60%) had bleedings more than once per month, 4 of them (26.7%) had bleedings more than once per week.

For control the bleeding episode it was need one injection of Innonafactor in 55.8% cases, three injections in 14%. 28.2% cases didn't need plus injections of Innonafactor.

Residual activity of factor IX ≥1% in 72 hours after infusion was registered in 100% patients with severe hemophilia b, IX ≥2% – in 80% patients with mild form of disease.

We registered 5 AE. All of them were count as easy and hadn't have relation with Innonafactor.

#### Summary:


For today we report our experience with new Russian recombinant factor IX Innonafactor. The prophylactic treatment was effective in all patients. During the treatment we didn't register SAE. All AE during the treatment were not related to Innonafactor. There were not register thrombotic complications, allergic reactions, the formation of an inhibitor to the factor IX.

**Disclosures** No relevant conflicts of interest to declare.

- ↯\* Asterisk with author names denotes non-ASH members.

© 2017 by The American Society of Hematology

[Previous](#)



[Table of Contents](#)  
 Volume: 130  
 Issue: Suppl 1  
 Pages: 4895  
 DOI: <https://doi.org/>

- Email
- Alerts
- Citation Tools
- Cite This
- Request Permissions
- Share

- Tweet
- Facebook
- Google+

### Jump to

- Article
- Info & Metrics

### Related Articles

No related articles found.

### Potential Articles of Interest

- |   |   |
|---|---|
| <p><b>Safety and Efficacy of New Moroctocog Alfa Drug (Octofactor) in Prophylactic Treatment in Adolescent Patients with Severe and Moderate Hemophilia a</b><br/>Ekaterina Shiller et al., Blood</p>   | <p><b>Pharmacokinetics, Efficacy and Safety of BAX326, a Novel Recombinant Factor IX: A Prospective, Controlled, Multicenter Study in Previously Treated Patients with Severe (FIX Level &lt; 1%) or Moderately Severe (FIX Level ≤ 2%) Hemophilia B.</b><br/>Jerzy Windyga et al., Blood</p> |
| <p><b>Safety and Efficacy of New Nonacog Alfa Drug (Innonafactor) in Prophylactic Treatment in Patients with Severe and Moderate Hemophilia B</b><br/>Maria Shamina et al., Blood</p>   | <p><b>Alprolix shows promise in treatment of severe pediatric hemophilia B</b><br/>Healio</p>   |
| <p><b>Predicting FIX Activity in Prophylaxis Patients Using Recombinant FIX Fc Fusion Protein for Treatment of Bleeding Episodes</b><br/>Jerry S Powell et al., Blood</p>   | <p><b>FDA approves Eloctate for hemophilia A</b><br/>Healio</p>   |
| <p><b>Clinical Outcomes in Adults/Adolescents with Hemophilia B Treated Long Term with Recombinant Factor IX Fc Fusion Protein (rFIXFc) Prophylaxis: Interim Results of the B-Yond Extension Study</b><br/>Tadashi Matsushita et al., Blood</p> | <p><b>Hemophilia B Gene Therapy With a High Specific Activity Factor IX Variant</b><br/>PracticeUpdate</p>  |
| <p><b>Evaluation of Two Secondary Prophylaxis Regimens of Recombinant Factor IX(r-IX) in Moderately Severe to Severe( FIX ≤2%) Hemophilia B Patients</b><br/>Pablo Rendo et al., Blood</p>  | <p><b>Gene Therapy Could Potentially Improve Quality of Life for Hemophilia Patients</b><br/>PracticeUpdate</p>   |

Powered by **TREND MD**



[Previous](#)

[Back to top](#)



Leading the way in experimental and clinical research in hematology

**American Society of Hematology**  
 2021 L Street NW, Suite 900, Washington, DC 20036  
 Phone 202-776-0544 | Fax 202-776-0545

- |   |  |  |   |
|---|--|--|---|
| <a href="#">Current Issue</a><br><a href="#">First Edition</a><br><a href="#">Collections</a><br><a href="#">All Issues</a><br><a href="#">Abstracts</a><br><a href="#">Video Library</a> | <a href="#">About <i>Blood</i></a><br><a href="#">Subscriptions</a><br><a href="#">Newsroom</a><br><a href="#">Copyright</a><br><a href="#">Public Access</a><br><a href="#">Permissions</a> | <a href="#">Submit to <i>Blood</i></a><br><a href="#">Blood App</a><br><a href="#">Alerts</a><br><a href="#">RSS</a><br><a href="#">Contact Us</a><br><a href="#">Order Reprints</a> | <b>Information for:</b><br><a href="#">Authors</a><br><a href="#">Subscribers</a><br><a href="#">Institutions/Librarians</a><br><a href="#">Advertising in <i>Blood</i></a><br><a href="#">Terms and Conditions</a> |
|---|--|--|---|